{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:18:30Z","timestamp":1762078710593},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,8,4]],"date-time":"2005-08-04T00:00:00Z","timestamp":1123113600000},"content-version":"vor","delay-in-days":4843,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[1992,5]]},"abstract":"<jats:p><jats:bold>Summary: <\/jats:bold> Felbamate (2\u2010phenyl\u20101,3\u2010propanediol dicarbamate, FBM) was subjected to a series of carefully selected in vivo and in vitro tests to provide additional insight into mechanism of action, margin of safety, and clinical potential. FBM was effective against intracere broventricular (i.c.v.) N\u2010methyl\u2010D\u2010aspartate (NMDA)\u2010induced clonus and i.c.v. NMDA\u2010 and quisqualic acid (quis)\u2010induced forelimb tonic extension in mice and ineffective against i.c.v. quis\u2010induced clonus in mice. FBM was also effective in preventing the expression of Stage 5 kindled seizures in corneal\u2010kindled rats. The calculated protective indices (rotorod median toxic dose divided by anticonvulsant median effective dose) ranged from 28 to 146 for those tests in which FBM displayed activity. With the in vitro tests, FBM did not significantly displace [<jats:sup>3<\/jats:sup>H]MK\u2010801 from its binding site. In contrast, FBM was effective in blocking sustained repetitive firing in mouse spinal cord neurons grown in tissue culture (median inhibitory concentration 67 \u03bcg\/ml). This effect on repetitive firing suggests indirectly that FBM modulates sodium channel conductance. The results, when compared to similar data for phenytoin, carbamazepine, valproate, and ethosuximide, support the concept that FBM is a relatively nontoxic agent with a unique profile of anticonvulsant action, a broad margin of safety, and a clinical potential that includes at least generalized tonic\u2010clonic and complex partial seizures.<\/jats:p>","DOI":"10.1111\/j.1528-1157.1992.tb01711.x","type":"journal-article","created":{"date-parts":[[2005,8,4]],"date-time":"2005-08-04T15:16:03Z","timestamp":1123168563000},"page":"564-572","source":"Crossref","is-referenced-by-count":119,"title":["A Neuropharmacological Evaluation of Felbamate as a Novel Anticonvulsant"],"prefix":"10.1111","volume":"33","author":[{"given":"H. Steve","family":"White","sequence":"first","affiliation":[]},{"given":"Harold H.","family":"Wolf","sequence":"additional","affiliation":[]},{"given":"Ewart A.","family":"Swinyard","sequence":"additional","affiliation":[]},{"given":"Gwendolyn A.","family":"Skeen","sequence":"additional","affiliation":[]},{"given":"R. Duane","family":"Sofia","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2005,8,4]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1980.tb04321.x"},{"key":"e_1_2_1_3_1","first-page":"81","volume-title":"Probit analysis","author":"Finney DJ","year":"1971"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1988.tb03750.x"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05458.x"},{"key":"e_1_2_1_6_1","first-page":"175","volume-title":"Neuroscience approached through tissue culture","author":"Hertz L","year":"1982"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(88)91107-9"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(88)90839-6"},{"key":"e_1_2_1_9_1","first-page":"661","article-title":"Felbamate in partial seizures: results of phase II clinical trial","volume":"30","author":"Leppik IE","year":"1989","journal-title":"Epilepsia"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(88)90054-X"},{"key":"e_1_2_1_11_1","first-page":"779","article-title":"Multiple actions of phenytoin on mouse spinal cord neurons in culture","volume":"227","author":"McLean MJ","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_12_1","first-page":"727","article-title":"Carbamazepine and 10,11\u2010epoxycarbamazepine produce use\u2010 and voltage\u2010dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture","volume":"238","author":"McLean MJ","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05809.x"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0301-0082(80)90006-4"},{"key":"e_1_2_1_15_1","first-page":"117","volume-title":"New anticunvulsant drugs","author":"Perhach JL","year":"1986"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(72)90177-0"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1152\/jn.1977.40.5.1132"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1988.tb01818.x"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05300.x"},{"key":"e_1_2_1_20_1","first-page":"649","article-title":"Open pilot study of felbamate (ADD 03055) in partial seizures","volume":"27","author":"Sheridan PH","year":"1986","journal-title":"Epilepsia"},{"key":"e_1_2_1_21_1","first-page":"A1068","article-title":"Effect of prototype anti convulsants on N\u2010methyl\u2010D\u2010aspartate (NMDA)\u2010induced seizures in mice","volume":"2","author":"Singh NA","year":"1988","journal-title":"FASEB J"},{"issue":"14","key":"e_1_2_1_22_1","first-page":"240","article-title":"Effect of prototype anti convulsant agents on quisqualic acid (quis)\u2010induced seizures in mice","volume":"6","author":"Singh NA","year":"1988","journal-title":"SOC Neurosci Abstr"},{"key":"e_1_2_1_23_1","first-page":"307","article-title":"Development of kindled seizures following electrical stimulation via the cornea","volume":"16","author":"Skeen G","year":"1990","journal-title":"Soc Neurosci Abstr"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1986.tb03497.x"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1987.tb04221.x"},{"key":"e_1_2_1_26_1","first-page":"85","volume-title":"Antiepileptic drugs","author":"Swinyard EA","year":"1989"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-100-24603"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1985.tb05699.x"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1157.1992.tb01711.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1157.1992.tb01711.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:38:26Z","timestamp":1695861506000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1157.1992.tb01711.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1992,5]]}},"alternative-id":["10.1111\/j.1528-1157.1992.tb01711.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1157.1992.tb01711.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,5]]}}}